Record Details

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?

Hematology Reports

View Archive Info
 
 
Field Value
 
Authentication Code dc
 
Title Statement Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
 
Added Entry - Uncontrolled Name Giovanni Martinelli; Institute of Hematology and Medical Oncology "L. e A. Seràgnoli", Bologna, Italy
Simona Soverini; Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna
Ilaria Iacobucci; Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna
Cristina Papayannidis; Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna
Daniela Cilloni; Division of Hematology and Internal Medicine, Department of Clinical and Biological Science, University of Turin
Michele Baccarani; Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna
Acknowledgements: Supported by European LeukemiaNet, FIRB 2006, A.I.L., A.I.R.C., Fondazione del Monte di Bologna e Ravenna.
 
Uncontrolled Index Term Medicine; Hematology; Leukemia;
Aurora kinase inhibitors; Chronic Myelogenous Leukemia
 
Summary, etc. At present, there are no compounds in clinical development in the field of chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) that have been documented to harbor significant activity against the imatinib-resistant T315I mutation. Recent reports on the pre-clinical activity of some emerging tyrosine kinase inhibitors such as ON012380, VX-680 and PHA-739358 promise possible clinical efficacy against this specific Bcr-Abl mutant form. Here, we focus on the role of aurora kinase inhibitor VX-680 and PHA-739358 in blocking the leukemogenic pathways driven by wild-type and T315I-Bcr-Abl in CML or Ph+ ALL by reviewing recent research evidence. We also discuss the possibility of employing aurora kinase inhibitors as a promising new therapeutic approach in the treatment of CML and Ph+ ALL patients resistant to first and second generation TK inhibitors.   
 
Publication, Distribution, Etc. PAGEPress Publications
2009-03-13
 
Electronic Location and Access application/pdf
text/html
http://www.pagepress.org/journals/index.php/hr/article/view/hr.2009.e1
 
Data Source Entry Hematology Reports; Vol 1, No 1 (2009); e1
 
Language Note en
 
Terms Governing Use and Reproduction Note <p>PAGEPress has chosen to apply the <a href="http://creativecommons.org/licenses/by-nc/3.0/" target="_blank">Creative Commons Attribution License</a> (CCAL) to all manuscripts to be published. </p> <p>An Open Access Publication is one that meets the following two conditions:</p> <ol><li>The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li><li>A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li></ol> Authors who publish with this journal agree to the following terms: 1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. 3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).